Active Implantable Medical Devices (AIMD) Market - Forecasts from 2023 to 2028

The global active implantable medical devices market is expected to grow at a CAGR of 7.79% from US$27.017 billion in 2021 to US$45.686 billion by 2028.

Technology breakthroughs are driving the market for active implantable medical devices (AIMDs), which address the growing incidence of chronic diseases, especially in the aging population. The need for active implantable medical devices is driven by patient preference, government funding, and increased awareness. Innovation is further fueled by ongoing R&D projects and extended indications for already-existing products.

Furthermore, according to the National Library of Medicine, numerous aspects of medicine are utilizing artificial intelligence (AI), including patient-specific diagnoses. In the upcoming years, growth in the artificial intelligence medical device (AIMD) industry is anticipated. Major nations are currently setting up frameworks and regulations to take the lead in the market for medical artificial intelligence. The Act on fostering the medical devices industry and supporting innovative medical devices was proposed by the Republic of Korea and is being implemented in anticipation of the development of AIMDs.

The rising prevalence of diseases among the geriatric population

The active implantable medical device market is impacted greatly by the aging population's increasing incidence of chronic diseases. The aging population is associated with an increased incidence of ailments like diabetes, neurological problems, and cardiovascular diseases, all of which call for sophisticated medical care. Since AIMDs can monitor, manage, or treat chronic illnesses, they play a critical role in enhancing the quality of life for older adults. Owing to the growing need for implantable devices brought on by this demographic trend, the market is expected to develop as patients and healthcare providers look for practical ways to handle the complicated healthcare requirements that come with aging and chronic illnesses.

As per the Administration of Community Living, in 2020, there were 55.7 million Americans 65 years of age or older in the United States. More than one in every six Americans, or 17% of the population, was represented by them. Since 2010, the number of Americans over 65 has climbed by 15.2 million (or 38%), while the number of people under 65 has increased by 2%. Additionally, the number of Americans in the 45–64 age group (who will become 65 years old during the next 20 years) grew by 1% from 81.8 million to 82.8 million between 2010 and 2020. The number of Americans sixty years of age and above rose from 57.5 million to 76.5 million, a 33% rise.

Furthermore, according to the National Library of Medicine, the main causes of disability and early mortality among India's senior population are chronic illnesses.  In India, it is estimated that 21% of the elderly suffer from at least one chronic illness. Chronic disease affects 29% of older people in urban settings and 17% of senior people in rural areas. Of all chronic disorders, hypertension and diabetes account for over 68%. Kerala has the highest rate of chronic disease prevalence (54%), ahead of Andhra Pradesh (43), West Bengal (36), and Goa (32). 

As per the US Department of Health and Human Services, almost 25% of Americans will be 65 years of age or older by 2060. Chronic health issues like diabetes, osteoporosis, and Alzheimer's disease are more common among older people. Furthermore, falls account for one in three adult falls in the older population, making them a major source of injuries. Seniors who engage in physical activity can reduce their risk of developing chronic illnesses and injuries from falls.

The United States in North America is predicted to hold the largest market share in the market

Active implantable medical devices (AIMD) are a type of medical device that is completely or partially implanted in the human body for therapeutics or diagnostic purposes. The devices enable doctors and healthcare professionals to constantly monitor a patient’s body for an extended period. Such devices are mainly used for monitoring heart conditions, and with the growing prevalence and deaths via cardiovascular disease in the United States, the market demand for AIMD is anticipated to witness an upward trajectory. According to the Centers for Disease Control and Prevention, in 2022, the number of deaths that occurred via heart disease reached 6,99,659 which signified an increase of 4,659 in comparison to 2021’s death count.  Moreover, as per the same source, heart disease is one of the major causes of death for women, men, and people of ethnic or racial groups in the United States, and every year nearly 6,05,000 people in America experience their first heart attack.

Moreover, the growing old age population in the United States is further expected to increase the heart disease prevalence rate thereby bolstering the demand for active implantable medical devices. According to the World Bank’s data, in 2022, the old age population accounted for 17% of the overall population of the United States.  Furthermore, technological advancements in patient monitoring coupled with product launches of AIMDs are also acting as an additional driving factor. For instance, in July 2023, Abbott Laboratories announced that the company received U.S. FDA’s approval for its “AVEIR™” dual-chamber pacemaker that would treat people with slow or abnormal heartbeat. The approval had enabled the company to provide its leadless pacing to millions of people across the United States. 

Market Key Developments

• In October 2023, the FDA approved the Epsila EVTM MRI SureScanTM defibrillation lead and the Aurora EV-ICDTM MRI SureScanTM (Extravascular Implantable Cardioverter-Defibrillator) for use in treating dangerously fast heart rhythms that may result in sudden cardiac arrest (SCA). Medtronic plc, a leader in healthcare technology globally, was the recipient of this approval. The lead, or thin wire, for the Aurora EV-ICD system, is positioned beneath the breastbone, away from the heart and veins, and it offers the life-saving advantages of conventional transvenous ICDs for the first time. The Aurora EV-ICD is a device that resembles conventional transvenous ICDs in terms of size, structure, and longevity. 
• In April 2022, the medical device startup FineHeart S.A., which is creating the completely implantable cardiac output restoration system (ICOMS) FLOWMAKER® to meet the unmet requirements of patients with severe heart failure, announced that the CNIPA has awarded its first two patents. These new patents add to the company's robust global portfolio of 20 families and over 78 patents that cover the idea, development, manufacturing, and surgical implantation of the FLOWMAKER®, the world's first physiological heart assist device created by French cardiologists specializing in rhythm and electrophysiology that treats severe heart failure.
• In February 2021, Abbott's neuromodulation clinician programmer app and its patient controller app, which can be used on compatible Apple smartphone devices, became the first Active Implantable Medical Devices products that BSI has certified to comply with the Medical Devices Regulation (MDR) (EU 2017/745) through its Notified Body in the Netherlands. All Class III Active Implantable Medical Devices are governed by the strictest regulations. This also applies to their accessories.

Segmentation:

By Product

• Ventricular Assist Devices
• Neurostimulators
• Implantable Cardiac Pacemakers
• Cochlear Implants
• Others

By End-User

• Hospitals & Clinics
• Ambulatory Surgical Centers

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others